- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07304375
Effects of Exercise and Sleep on Motor Learning and Functional Abilities in Multiple Sclerosis (ExSiMS)
Effects of Aerobic Exercise and Daytime Sleep on Neurorehabilitation and Functional Abilities in Multiple Sclerosis: Evidence of Training the Brain in Neurorehabilitation
The ExSiMS study is a randomized, controlled crossover study including 20 individuals (18-70 years) diagnosed with relapsing remitting Multiple Sclerosis (MS) This project investigates, through behavioral and neurophysiological measurements, how aerobic exercise on an ergometer bike and sleep in the form of a nap and overnight sleep may enhance cortical motor skill learning evaluated by a complex hand motor skill test and thereby improve functional capacity in individuals with MS. Beyond the effect on motor skill learning, the project investigate the effect on electroencephalography (EEG) - electromyography (EMG) coherence.
The study hypothesizes that individuals with neurological conditions, such as multiple sclerosis (MS), may experience beneficial effects on specific motor rehabilitation through systematically planned cardiovascular exercise and sleep scheduling, due to positive impacts on memory consolidation.
Aims:
- Investigate the brain's neurophysiological responses and memory effects following a training intervention and, separately, sleep, in the form of a power nap, in individuals with MS.
- Examine whether these effects persist beyond the few days previously observed in healthy individuals by implementing a longer-term intervention.
- Explore whether the training effect is influenced by disease activity in the brain, such as during relapses and during immunosuppressive treatment.
- Assess whether the presence of abnormally reduced cognitive endurance (fatigue) affects the impact of the intervention involving exercise and sleep.
The study is based on documented positive effects of physical activity and sleep in both young and older adults, as well as in individuals recovering from stroke. The research thus offers promising perspectives for broader applications within neurorehabilitation, and particularly for MS, as the disease is associated with functional impairments. At the same time, both physical exercise and sleep represent meaningful interventions that should be thoughtfully integrated into rehabilitation strategies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The ExSiMS-project consists of both a proof-of-concept study and a longitudinal study.
In both studies, participants will perform a visuomotor accuracy tracking task (VATT) with their dominant hand on the main experimental days. The participants will wear EEG and EMG electrodes during the VATT. This will make it possible to investigate cortical activity during skill acquisition and later analyse the corticomuscular coherence. After the VATT, the participants will be randomized to either 20 min aerobic exercise on an ergometer bike, a short 30-minute nap or control (sitting rest). The interventions will run over a longer period of time in the longitudinal study.
The participants will be asked to do a retention test of the visuomotor accuracy tracking task 24 hours later.
The studies will run over more experiment days divided into two experiment blocks of at least two experiment days separated by between two weeks to three months.
Methods:
- Electroencephalography (EEG) and Electromyography (EMG)
- Actigraphy/Accelerometry
- Visuomotor Accuracy Tracking Task (VATT)
- Training on an Ergometerbike: Graded Exercise Test (GXT), High Intensity Interval Training (HIIT)
- Polysomnography (PSG)
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Caroline Sadolin Muushardt, MSc
- Phone Number: +45 46323200
- Email: cmuu@regionsjaelland.dk
Study Contact Backup
- Name: Martin Ballegaard, MD MPG PhD
- Email: mbag@regionsjaelland.dk
Study Locations
-
-
-
Copenhagen, Denmark, 2200
- Not yet recruiting
- Section of Movement and Neuroscience, Department of Nutrition, Exercise, and Sports, University of Copenhagen
-
Contact:
- Jesper Lundbye-Jensen, PhD
- Phone Number: +45 35 32 73 30
- Email: jlundbye@nexs.ku.dk
-
Contact:
- Caroline Sadolin Muushardt, MSc
- Email: cmuu@regionsjaelland.dk
-
Roskilde, Denmark, 4000
- Recruiting
- Zealand University Hospital Roskilde
-
Contact:
- Caroline Sadolin Muushardt, MSc
- Email: cmuu@regionsjaelland.dk
-
Contact:
- Martin Ballegaard, MD MPG PhD
- Phone Number: +45 46323200
- Email: mbag@regionsjaelland.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Competent individuals (aged 18-70) diagnosed with early relapsing-remitting MS
- Expanded Disability Status Score, 1 < EDSS < 4.5
- MRC muscle strength ≥ 4+ in the dominant hand
Exclusion Criteria:
- Implanted devices, such as pacemakers or stimulators
- Epilepsy or neuromuscular diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Aerobic Exercise - GXT
The aerobic exercise will consist of about 20 minutes of Graded Exercise Training (GXT) on an ergometer bike.
The experimenter will instruct and motivate the participant through the aerobic exercise.
|
The Aerobic Exercise Intervention consists of 20 minutes of Graded Exercise Test (GXT) on an ergometer bike.
The participants start with 5 minutes of warm-up.
The wattload will then be increased until exhaustion.
|
|
No Intervention: Control - Rest
The participant will rest in a sitting position in a quiet room for 20 minutes.
The participant is allowed to read or engage in similar quiet and sitting activities.
|
|
|
Experimental: Daytime Sleep - Nap
The participants will be asked to try and take a 30-minute nap.
The participant will be provided with a bed in a dark and quiet room.
|
The Daytime sleep consists of a 30-minute nap after the acquisition of the visuomotor accuracy tracking task.
The participants will be asked to rest in a supine position in a bed in a dark and quiet room.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motor/Skill Learning
Time Frame: Assessed on experiment days 1, 2, 3 and 4.
|
Visuomotor accuracy tracking task.
Online and offline effects.
Unit: Range from 0 (lowest) to 100 (highest) percent.
|
Assessed on experiment days 1, 2, 3 and 4.
|
|
Neurophysiological Measurement I - Cortical Activity
Time Frame: Assessed on experiment day 1, 2, 3 and 4.
|
Cortical activity will be measured with electroencephalography (EEG) during skill acquisition.
Unit: EEG Power in several frequency bands.
|
Assessed on experiment day 1, 2, 3 and 4.
|
|
Neurophysiological Measurement II - Muscular Activity
Time Frame: Assessed on experiment day 1, 2, 3 and 4.
|
Muscle activity will be measured with electromyography (EMG) during skill acquisition.
Unit: EMG amplitude.
|
Assessed on experiment day 1, 2, 3 and 4.
|
|
Neurophysiological Measurement III - Corticocortical Functional Connectivity
Time Frame: Assessed on experiment day 1, 2, 3 and 4.
|
Corticocortical functional connectivity will me measured as functional coupling in EEG during skill acquisition.
Unit: functional coupling in EEG (scale 0-1).
|
Assessed on experiment day 1, 2, 3 and 4.
|
|
Neurophysiological Measurement IV - Corticomuscular Functional Connectivity
Time Frame: Assessed on experiment day 1, 2, 3 and 4.
|
Corticomuscular functional connectivity during skill acquisition will be measured with functional coupling between EEG and EMG.
Unit: functional coupling in EEG-EMG.
|
Assessed on experiment day 1, 2, 3 and 4.
|
|
Neurophysiological Measurement V - Muscular Functional Connectivity
Time Frame: Assessed on experiment day 1, 2, 3 and 4.
|
Muscular functional connectivity during skill acquisition will be assessed using EMG-EMG coherence between M. Abductor Pollicis Brevis and First Dorsal Interosseus.
Unit: EMG-EMG coherence (0-1)
|
Assessed on experiment day 1, 2, 3 and 4.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Actigraphy
Time Frame: Assessment from day 0 to experiment day 4.
|
Measurement of sedentary, moderate, and vigorous activity during the experiment period.
Unit = hours:min.
|
Assessment from day 0 to experiment day 4.
|
|
Sleep quality - self reported sleep latency.
Time Frame: Assessed at the days leading up to experiment days 1,2,3, and 4.
|
Self-reported sleep latency will be measured by the National Sleep Foundation Sleep Diary translated to Danish.
Unit: Hour:minutes.
|
Assessed at the days leading up to experiment days 1,2,3, and 4.
|
|
Sleep quality - Self reported sleep duration
Time Frame: Assessed at the days leading up to experiment days 1,2,3, and 4.
|
Self-reported sleep duration will be measured by the National Sleep Foundation Sleep Diary translated to Danish.
Unit: Hour:min.
|
Assessed at the days leading up to experiment days 1,2,3, and 4.
|
|
Physical fitness level - work load
Time Frame: Assessed on either experiment day 1 or 3.
|
Graded exercise test (GXT) on an ergometer bike - maximum work load.
Unit: watt
|
Assessed on either experiment day 1 or 3.
|
|
Physical fitness level - heart rate
Time Frame: Assessed on either experiment day 1 or 3
|
Graded exercise test (GXT) on an ergometer bike - heart rate measured with a chest strap.
Unit: beats per minute (BPM).
|
Assessed on either experiment day 1 or 3
|
|
Physical fitness level - rating of perceived exertion
Time Frame: Assessed on either experiment day 1 or 3.
|
Graded exercise test (GXT) on an ergometer bike - rating of perceived exertion with the Borg scale.
Unit: Borg scale 6-20 (6 = rest, 20 = maximal exhaustion).
|
Assessed on either experiment day 1 or 3.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wakefulness
Time Frame: Assessed on experiment days 1, 2, 3 and 4.
|
Wakefulness will be measured by the Stanford Sleepiness Scale: From 1 to 7. 1= "Feeling active and vital; alert; wide awake".
7= "Almost in reverie; sleep onset soon; lost struggle to remain awake.
X = Asleep".
|
Assessed on experiment days 1, 2, 3 and 4.
|
|
Handedness
Time Frame: Assessed on day 0.
|
Handedness questionnaire to determine the participant's dominant hand.
Unit: Laterality index (-100.00
(lefthanded) to 100.00 (righthanded).
|
Assessed on day 0.
|
|
Reaction Time Task
Time Frame: Assessed on day 0.
|
A simple Reaction Time Task on a computer.
Unit: ms.
|
Assessed on day 0.
|
|
The fatigue scale for motor and cognitive functions (FSMC)
Time Frame: Assessed on day 0.
|
Questionnaire measuring fatigue in individuals with Multiple Sclerosis.
Unit: FSMC_total = Points from 20-100 (≥ 43 Mild Fatigue, ≥ 53 Moderate Fatigue, ≥ 63 Severe Fatigue).
|
Assessed on day 0.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Martin Ballegaard, Zealand University Hospital - Roskilde
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Behavior
- Multiple Sclerosis
- Motor Activity
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Exercise
Other Study ID Numbers
- SJ-1040 (Other Identifier: De Videnskabelige Komitéer)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Aerobic Exercise
-
Riphah International UniversityCompleted
-
Sultan Abdulhamid Han Training and Research Hospital...RecruitingPhysical InactivityTurkey
-
University of FloridaAmerican Psychological Foundation; Clinical & Translational Science Institute; American Psychological Association (APA)CompletedBrain ConcussionUnited States
-
Radboud University Medical CenterUniversity Hospital, Bonn; University of Dublin, Trinity College; German Sport... and other collaboratorsCompletedMild Cognitive ImpairmentNetherlands, Ireland, Germany
-
National Defense Medical Center, TaiwanMinistry of Science and Technology, TaiwanRecruitingCardiology | PsychiatryTaiwan
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChildhood ObesityUnited States
-
National Yang Ming UniversityUnknownKnee OsteoarthritisTaiwan
-
RenJi HospitalRecruitingST-segment Elevation Myocardial Infarction (STEMI)China
-
Federal University of PelotasMinistry of Health, BrazilUnknownHypertension | Cardiovascular Disease | Chronic Kidney Disease | Chronic Renal DiseaseBrazil
-
Bezmialem Vakif UniversityCompletedSpecific Learning DisorderTurkey